|Videos|August 5, 2017

Once Labeled, Always Labeled: Addressing Misconceptions About Penicillin Allergies

Elizabeth Phillips, MD, FRCPC, FRACP, addresses the misconceptions about penicillin allergies.

Elizabeth Phillips, MD, FRCPC, FRACP, Professor of Medicine, Pharmacology, and Pathology, Vanderbilt University Medical Center, addresses the misconceptions about penicillin allergies.

Interview Transcript (slightly modified for readability)

“I think that there’s a lot of misperceptions about antibiotic allergy, and penicillin in particular. There’s this overriding superstition that once [someone’s] labeled, [they’re] always labeled, and I think the educational aspect of it is huge.

I think education around the fact that most patients, in fact, 99% of patients that are labeled, are unlikely to have true penicillin allergy. Penicillin allergy is something that does tend to wane over time; and so, even if a patient mechanistically has had a defined true allergy—a serious, life-threatening allergy—at some point in their life, they tend to lose the tendency to that over time to the point that after about 10 years, there’s a very good chance they would be no longer allergic.

I think the take-home message is it’s always worth considering—regardless of the severity of the reaction or the history—the ‘work-up’ of somebody that has actually been labeled with penicillin allergy.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.